Ferritin Dynamics in Malignant Lymphoma

Abstract

The clinical and pathophysiological implications of ferritin dynamics in terms of circulating ferritin secreting cells (FSC) were evaluated in patients with various hematological malignancies using a reverse hemolytic plaque assay.
The number of FSC contained in circulating monocytes and lymphocytes were greatly increased in patients with malignant lymphoma. The increase in the number of FSC was more prominent in patients with advanced disease, whereas it was less prominent in those in early stages or in complete remission following adequate chemotherapy.
The enumeration of FSC in patients with malignant lymphoma seems to help us evaluate the response to treatment.